BillionToOne Inc Ordinary Shares - Class A BLLN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance
BillionToOne to Participate in Two Upcoming Investor Conferences
7 healthcare stocks that stand out as investors pay up for the sector
7 healthcare stocks that stand out as -2-
BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026
BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference
BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin
/C O R R E C T I O N — BillionToOne/
Trading Information
- Previous Close Price
- $112.39
- Day Range
- $106.70–112.40
- 52-Week Range
- $62.00–150.27
- Bid/Ask
- $110.50 / $112.24
- Shares Outstanding
- 47.77M
- Market Cap
- $5.19B
- Volume/Avg
- 16,444 / 657,303
Key Statistics
- Price/Earnings (Normalized)
- 101.92
- Price/Sales
- 5.46
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Growth
- Total Number of Employees
- 713
- Website
- https://www.billiontoone.com
Valuation
Metric | BLLN |
|---|---|
Price/Earnings (Normalized) | 101.92 |
Price/Book Value | 9.45 |
Price/Sales | 5.46 |
Price/Cash Flow | 23.84 |
Price/Earnings
BLLN
Financial Strength
Metric | BLLN |
|---|---|
Quick Ratio | 10.72 |
Current Ratio | 11.25 |
Interest Coverage | 1,193.85 |
Quick Ratio
BLLN
Profitability
Metric | BLLN |
|---|---|
Return on Assets (Normalized) | 13.61% |
Return on Equity (Normalized) | 23.19% |
Return on Invested Capital (Normalized) | 13.71% |
Return on Assets
BLLN
Diagnostics & Research Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | LOCK|tyF^&$& | LOCK|&L | $251B | |||
| Danaher Corp DHR | LOCK|<GK#^T$m | LOCK|>r | $159B | |||
| IDEXX Laboratories Inc IDXX | LOCK|G!T@>Gs | LOCK|!wM | $53B | |||
| Agilent Technologies Inc A | LOCK|N^@>%kz | LOCK|>n | $48B | |||
| Waters Corp WAT | LOCK|ls#&Cjz | LOCK|&@ | $44B | |||
| IQVIA Holdings Inc IQV | LOCK|M^$GC@^ | LOCK|?@hf | $44B | |||
| Mettler-Toledo International Inc MTD | LOCK|!!!<@?S | LOCK|z!N$ | $34B | |||
| Illumina Inc ILMN | LOCK|v^xZv@@ | LOCK|scP$^ | $31B | |||
| Labcorp Holdings Inc LH | LOCK|Slt<?!%n | LOCK|XyS@ | $29B | |||
| Quest Diagnostics Inc DGX | LOCK|gy^C?<y | LOCK|v@<j | $28B |
United States